Neutrino Development Corp. v. Sonosite, Inc.

512 F. Supp. 2d 1004, 2007 U.S. Dist. LEXIS 24234, 2007 WL 1040697
CourtDistrict Court, S.D. Texas
DecidedMarch 30, 2007
DocketCivil Action H-01-2484
StatusPublished

This text of 512 F. Supp. 2d 1004 (Neutrino Development Corp. v. Sonosite, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Neutrino Development Corp. v. Sonosite, Inc., 512 F. Supp. 2d 1004, 2007 U.S. Dist. LEXIS 24234, 2007 WL 1040697 (S.D. Tex. 2007).

Opinion

MEMORANDUM AND ORDER

JOHN D. RAINEY, District Judge.

Pending before the Court is Defendant’s Motion for Exceptional Case and Attorneys’ Fees (Dkt.# 368). The Court, after reviewing the motion, the responses of the parties and the relevant law, is of the opinion that the motion should be DENIED.

Factual and Procedural Background

In May of 1999, Richard Redaño (“Reda-no”) filed a patent application (“the '021 patent application”) with the Patent and Trademark Office (“PTO”) disclosing a “method and apparatus for penile hemody-namic stimulation, monitoring, and drug delivery acceleration.” 1 The original application contained 20 claims. In November 1999, Redaño wrote a letter to Dr. Juin-Jet Hwang, Chief Technology Officer of Sonosite Inc. (“Sonosite”), offering to *1006 disclose the claims of the '021 patent application upon execution of a nondisclosure agreement, summarizing the purpose of the invention to be patented, and inquiring as to whether Sonosite would be interested in licensing the '021 patent once issued. 2 Redaño received an email response from Dr. Hwang indicating that Sonosite was not interested in therapeutic ultrasound technology. In response, Redaño sent a facsimile to Dr. Hwang cautioning that “[o]nly time will tell the degree to which the pending applications will cover imaging technology.” 3

On February 4, 2000, the PTO rejected all 20 claims of the '021 patent application on various grounds. 4 On May 4, 2000, Redaño filed an “Amendment and Response to First Action” in which he added new claims 21-37. 5 In new claim 30, the language “sized to be hand held” appeared for the first time with regard to the ultra-sonography generator component of the invention. On July 19, 2000, the PTO notified Redaño that he had to elect between prosecution of claims 1-2, 8-9, 11-12, 14-16, 18, and 21 (pertaining to the therapeutic device and methods) or claims 22-37 (pertaining to the diagnostic device). 6 On July 27, 2000, by way of telephone interview, Redaño elected to prosecute claims 22-37 without traverse.

On July 31, 2000, the PTO rejected claims 22-37 “under the doctrine of obviousness-type double patenting as being un-patentable over claims 1-20 of U.S. Patent No. 5931783.” This action, however, was overcome in November 2000 when Redaño filed a terminal disclaimer with regard to the '783 patent (also held by Redaño). At that time, Redaño also amended the claims of the '021 patent application by canceling claims 29 and 37, and adding new claims 38-50. On April 24, 2001, the '021 patent issued with 27 claims taken from portions of application claims 22-50.

On July 24, 2001, Neutrino Development Corp. (“Neutrino”), which had licensed the 2C021 patent from Redaño, filed the present infringement action against Sonosite. On August 29, 2001, Neutrino filed a motion for a preliminary injunction (Dkt.# 8), which the Court denied by Order of October 4, 2001 (Dkt.# 30). On February 20, 2002, after extensive briefing, the Court held a one-day Markman hearing and subsequently issued an Order on August 20, 2003 construing certain claims of the '021 patent (Dkt.# 125). Based on that claim construction, the Court later found that four devices manufactured and marketed by Sonosite (the Sonosite 180, SonoHeart, 180 PLUS, and the SonoHeart PLUS) literally infringed the '021 patent (Dkt.# 162). However, after considering the prosecution of the '021 patent in greater detail, the Court found that Redaño had improperly added “new matter” when the '021 patent application was amended in May of 2000. Consequently, the Court found that certain claims of the '021 patent at the center of this lawsuit are invalid for new matter and entered a final judgment in favor of Sonosite (Dkt.# 363 and Dkt. # 364).

Sonosite has filed the present post-judgment motion requesting that the Court find that this is an “exceptional case” under 35 U.S.C. § 285 and award attorneys fees and certain non-taxable costs to Sono-site as the prevailing party.

Analysis

35 U.S.C. § 285 allows a court to award attorneys fees to a prevailing party *1007 in an “exceptional case.” 7 An award of attorney fees under § 285 involves a two-part determination. First, a district court must determine whether the prevailing party has proven an exceptional case by clear and convincing evidence. Forest Labs., Inc. v. Abbott Labs., 339 F.3d 1324, 1327 (Fed.Cir.2003) (citing Ruiz v. A.B. Chance Co., 234 F.3d 654, 669 (Fed.Cir.2000)). Second, if the district court finds that the case is exceptional, it must then determine whether an award of attorney fees is appropriate. Id. An award of attorneys fees is appropriate “where it would be grossly unjust that the winner be felt to bear the burden of his own counsel.” J.P. Stevens Co. v. Lex Tex Ltd., Inc., 822 F.2d 1047, 1052 (Fed.Cir.1987) (emphasis in original).

The “clear and convincing” standard of proof is an intermediate standard which lies somewhere between “beyond a reasonable doubt” and a “preponderance of the evidence.” Addington v. Texas, 441 U.S. 418, 425, 99 S.Ct. 1804, 60 L.Ed.2d 323 (1979). Although not susceptible to precise definition, “clear and convincing evidence” has been described as evidence which produces in the mind of the trier of fact “an abiding conviction that [the] truth of the factual contentions are ‘highly probable.’ ” Colorado v. New Mexico, 467 U.S. 310, 316, 104 S.Ct. 2433, 81 L.Ed.2d 247 (1984); see also Shafer v. Army & Air Force Exchange Srvc., 376 F.3d 386 (5th Cir.2004) (instructing that clear and convincing evidence is “that weight of proof which ‘produces in the mind of the trier of fact a firm belief or conviction as to the truth of the allegations sought to be established, evidence so clear, direct and weighty and convincing as to enable the fact finder to come to a. clear conviction, without hesitancy,. of the truth of precise facts’ of the case.” (quoting In re Medrano, 9 56 F.2d 101, 102 (5th Cir.1992))).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
512 F. Supp. 2d 1004, 2007 U.S. Dist. LEXIS 24234, 2007 WL 1040697, Counsel Stack Legal Research, https://law.counselstack.com/opinion/neutrino-development-corp-v-sonosite-inc-txsd-2007.